Clinical pharmacology of <scp>AMG</scp> 181, a gut‐specific human anti‐α<sub>4</sub>β<sub>7</sub> monoclonal antibody, for treating inflammatory bowel diseases

Pan, Wei‐Jian; Köck, Kathleen; A. Rees, William; Sullivan, Barbara; M. Evangelista, Christine; Yen, Mark; M. Andrews, Jane; Radford‐Smith, Graham; J. Prince, Peter; Reynhardt, Kaz; R. Doherty, David; Patel, Sonal; D. Krill, Christine; Zhou, Kefei; Shen, Jing; Smith, Lynn; M. Gow, Jason; Lee, Jonathan; M. Treacy, Anthony; Yu, Zhigang; M. Platt, Virginia; Borie, Dominic

doi:10.1111/bcp.12418

Public

Clinical pharmacology of AMG 181, a gut‐specific human anti‐α4β7 monoclonal antibody, for treating inflammatory bowel diseases

Published in British Journal of Clinical Pharmacology • May 7, 2014

Authors:

Wei‐Jian Pan

Kathleen Köck

William A. Rees

Abstract

AIMS: AMG 181 pharmacokinetics/pharmacodynamics (PK/PD), safety, tolerability and effects after single subcutaneous (s.c.) or intravenous (i.v.) administration were evaluated in a randomized, double-blind, placebo-controlled study. METHODS: Healthy male subjects (n= 68) received a single dose of AMG...

Subject

Pharmacokinetics

Placebo

Cmax

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!